Evidence map›Paper›PMID 34045121›Full record

ReviewTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2021

Convalescent plasma to treat COVID-19: Following the Argentinian lead.

Pierre Tiberghien, Eric Toussirot, Pascale Richard, Pascal Morel, Olivier Garraud

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Pierre TiberghienEtablissement Français du Sang, La Plaine St Denis, France; UMR RIGHT 1098 Inserm, Université de Franche-Comté, Etablissement Français du Sang, Besançon, France. Electronic address: pierre.tiberghien@efs.sante.fr.
Eric ToussirotUMR RIGHT 1098 Inserm, Université de Franche-Comté, Etablissement Français du Sang, Besançon, France; CHU Besançon, Inserm CIC 1431, Besançon, France.
Pascale RichardEtablissement Français du Sang, La Plaine St Denis, France.
Pascal MorelEtablissement Français du Sang, La Plaine St Denis, France; UMR RIGHT 1098 Inserm, Université de Franche-Comté, Etablissement Français du Sang, Besançon, France.
Olivier GarraudINSERM U1059, Faculty of Medicine of Saint-Etienne, University of Lyon-Saint-Etienne, St Etienne, France.
Inserm · FRÉtablissement Français du Sang · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ArgentinaCOVID-19COVID-19 SerotherapyHumansImmunization, PassiveAHFConvalescent plasmaCovid-19PlasmatherapyTransfusion

Identifiers

PMID34045121
PMCPMC8141263
OpenAlexW3165185755

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.